 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
 |
Veterinarian News
Funded Clinical Trial for Dogs with Hemangiosarcoma is now closed. |
07/26/2010
Trial Summary This clinical trial will evaluate a novel anti-cancer agent in a limited number of dogs with hemangiosarcoma. All dogs will receive study drug; there is no placebo. Dogs will receive the study drug as daily, oral treatment with evaluations performed once weekly for the first 28 days, then once monthly. Blood samples are collected throughout the study to assess the metabolism and biological activity of this drug. During the course of the study, dogs will not be allowed any holistic therapy, chemotherapy, prednisone therapy, non-steroidal anti-inflammatory therapy or other investigational therapies unless approved by the investigator and the sponsor. 
Treatment of Splenic Hemangiosarcoma with Doxorubicin and Palladia |
04/06/2010
Palladia has been shown not only to have activity against mast cell tumors but also against other cancers through anti-angiogenenic pathways. Dogs in this clinical trial will receive standard of care chemotherapy (Doxorubicin) post splenectomy. Two weeks after completing the chemotherapy course the patient will start Palladia. Patients enrolled in this study will receive free Palladia and a reduced cost on follow-up visits.
Clinical Trial For Canine Lymphoma is now closed to patients |
04/05/2010
Pet dogs that are enrolled in the study will receive a single dose of a novel, oral anti-cancer agent. Serial blood samples and lymph node aspirates will then be collected over a 24-hour period. Patients will return for evaluation 7 days after the single dose of therapy is administered. For participation, clients will receive $2000 towards oncology care.
What You Need to Know About Palladia (toceranib phosphate) |
06/22/2009
Pfizer recently received FDA approval for a novel drug, Palladia that is indicated for the treatment of mast cell tumors in dogs.
|
 |
Dr. Sheri Siegel